Mbrx Stock Forecast Next 3 Months
Moleculin biotech last issued its earnings data on november 11th, 2021. Your current $100 investment may be up to $778.48 in 2026.
Analyst projections state that mbrx is forecast to be at a low of $18 and a high of $29.
Mbrx stock forecast next 3 months. 3 years of cash and multiple targets for viruses and cancers. Why moleculin biotech is soaring 21% today dec. See rankings and related performance below.
Close price at the end of the last trading day (wednesday, 17th nov 2021) of the mbrx stock was $2.29. Earnings for moleculin biotech are expected to decrease in the coming year. Inflation rises and low interest rates pushing treasury and bond prices down
Only 3.00% of the stock of moleculin biotech is held by insiders. In order for the stock price to hit the forecast high, the stock would need to surge +538.77% from its current level, while the stock would need to crash 296.48% from its current level to reach the projected low. In addition to the average rating from wall street analysts, mbrx stock has a mean target price of 3.333.
Moleculin biotech stock was originally listed at a price of $48.00 in jun 2, 2016. Factors affecting the stock market. Revenue is forecast to grow 44.40% this quarter before jumping 19.20% for the next one.
Analyst price target for mbrx i we calculate consensus analyst ratings for stocks using the most recent rating from each wall street analyst that has rated a stock within the last twelve months. Stock trading at 20 percent discount to cash. Annual revenue (last year) $0.00:
Debt to equity ratio is likely to rise to 0.69 in 2021, whereas current ratio is likely to drop 4.73 in 2021. See more on the new outlook for october, november, december in anticipation of strong economic performance for the remainder 2021, heading into 2022. Mbrx's weekly volatility (6%) has been stable over the past year.
Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the. Moleculin biotech inc nasdaq:mbrx stock news. Each analyst's rating is normalized to a standardized rating.
The markets rally on bad news and go ballistic on any news that offers a small ray of hope. Moleculin biotech book value per share is fairly stable at the moment as compared to the past year. Et on investorplace.com moleculin biotech (mbrx) gets a buy rating from maxim group
Mbrx could be a diamond in the rough. This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. Moleculin biotech stock forecast, mbrx stock price prediction.
This means analysts expect the stock to increase 223.59% over the next 12 months. Monthly and daily opening, closing, maximum and minimum stock price outlook with smart technical analysis The reported ($0.15) eps for the quarter, beating the consensus estimate of ($0.20) by $0.05.
Only 10.37% of the stock of moleculin biotech is held by institutions. Economy had a meager showing in the 2nd quarter 2021; In the past three months, moleculin biotech insiders have not sold or bought any company stock.
Moleculin biotech does not have a long track record of dividend growth. This is 0.87% less than the trading day before tuesday, 16th nov 2021. Tangible asset value market capitalization.
Stock market forecast for next 3 to 6 months july 2020 update. During the day the stock fluctuated 3.57% from a day low at $2.24 to a day high of $2.32. Moleculin biotech has generated $0.00 earnings per share over the last year.
Moleculin biotech inc [mbrx] exchange: 1, 2020 at 12:47 p.m. We are definitely in a market that has no real order (the market of “disorder” is the new label for this bull market).
Moleculin biotech reported book value per share of 1.80 in 2020.
Komentar
Posting Komentar